Defence Therapeutics Collaboration Agreement with Orano to Develop the Next Generation of Targeted Radio-Immunotherapy for Cancer Advances
Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) has announced an update on its collaboration with Orano Support SAS to develop a novel Radio-Immuno-Conjugate (RIC) for cancer treatment. The project aims to create a next-generation RIC using Auger electron (AE) emitter elements combined with Defence's Accum® technology.
The Accum® technology addresses key limitations of RICs, such as endosomal sequestration and poor nuclear accumulation. Defence has developed various Accum® variants with different properties and has secured their production. The company has also patented the ability of some Accum® variants to deliver antibodies or antibody-conjugates into the nucleus.
Defence has arranged for in vitro and in vivo preclinical studies to be conducted by the radiopharmaceuticals team at the Canadian Nuclear Laboratories. This collaboration aims to open a new cancer therapy market based on promising radiotherapeutics using AE emitter radionuclides.
Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) ha annunciato un aggiornamento sulla sua collaborazione con Orano Support SAS per sviluppare un nuovo Radio-Immuno-Coniugato (RIC) per il trattamento del cancro. Il progetto mira a creare un RIC di nuova generazione utilizzando elementi emittenti di elettroni Auger (AE) combinati con la tecnologia Accum® di Defence.
La tecnologia Accum® affronta le principali limitazioni dei RIC, come la sequestrazione endosomiale e la scarsa accumulazione nucleare. Defence ha sviluppato varie varianti di Accum® con diverse proprietà e ha garantito la loro produzione. L'azienda ha anche brevettato la capacità di alcune varianti di Accum® di consegnare anticorpi o coniugati di anticorpi nel nucleo.
Defence ha organizzato studi preclinici in vitro e in vivo da condurre dal team di radiofarmaceutici presso i Canadian Nuclear Laboratories. Questa collaborazione mira ad aprire un nuovo mercato per la terapia del cancro basato su promettenti radio-terapeutiche utilizzando radionuclidi emittenti AE.
Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) ha anunciado una actualización sobre su colaboración con Orano Support SAS para desarrollar un nuevo Radio-Inmuno-Conjugado (RIC) para el tratamiento del cáncer. El proyecto tiene como objetivo crear un RIC de próxima generación utilizando elementos emisores de electrones Auger (AE) combinados con la tecnología Accum® de Defence.
La tecnología Accum® aborda las principales limitaciones de los RIC, como la sequestración endosomal y la acumulación nuclear deficiente. Defence ha desarrollado varias variantes de Accum® con diferentes propiedades y ha asegurado su producción. La empresa también ha patentado la capacidad de algunas variantes de Accum® para entregar anticuerpos o conjugados de anticuerpos en el núcleo.
Defence ha organizado estudios preclínicos in vitro y in vivo que serán realizados por el equipo de radiofármacos en los Laboratorios Nucleares Canadienses. Esta colaboración tiene como objetivo abrir un nuevo mercado de terapias contra el cáncer basado en prometedores radioterapéuticos que utilizan radionucleidos emisores de AE.
Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF)는 암 치료를 위한 새로운 방사면역결합체(RIC) 개발을 위해 Orano Support SAS와의 협력 업데이트를 발표했습니다. 이 프로젝트는 Defence의 Accum® 기술과 결합된 Auger 전자(AE) 방출 요소를 사용하여 차세대 RIC를 창출하는 것을 목표로 합니다.
Accum® 기술은 RIC의 주요 한계인 내포소 격리 및 낮은 핵 집중 문제를 해결합니다. Defence는 다양한 특성을 가진 여러 Accum® 변형을 개발하고 그 생산을 확보하였습니다. 또한 일부 Accum® 변형이 항체 또는 항체 결합체를 핵으로 전달할 수 있는 능력을 특허로 등록했습니다.
Defence는 캐나다 핵 연구소의 방사선 의약품 팀이 수행하는 in vitro 및 in vivo 전임상 연구를 준비했습니다. 이 협력은 AE 방출 방사성 동위 원소를 사용하는 유망한 방사선 치료제를 기반으로 하는 새로운 암 치료 시장을 개척하는 것을 목표로 합니다.
Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) a annoncé une mise à jour concernant sa collaboration avec Orano Support SAS pour développer un nouveau Radio-Immuno-Conjugué (RIC) pour le traitement du cancer. Le projet vise à créer un RIC de nouvelle génération utilisant des éléments émetteurs d'électrons Auger (AE) combinés avec la technologie Accum® de Defence.
La technologie Accum® s'attaque aux principales limitations des RIC, telles que la séquestration endosomale et la faible accumulation nucléaire. Defence a développé différentes variantes d'Accum® avec diverses propriétés et a sécurisé leur production. L'entreprise a également breveté la capacité de certaines variantes d'Accum® à délivrer des anticorps ou des conjugués d'anticorps dans le noyau.
Defence a organisé des études précliniques in vitro et in vivo qui seront réalisées par l'équipe des produits radiopharmaceutiques des Laboratoires Nucléaires Canadiens. Cette collaboration vise à ouvrir un nouveau marché de thérapies contre le cancer basé sur des radio-thérapeutiques prometteurs utilisant des radionucléides émetteurs d’AE.
Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) hat ein Update zu seiner Zusammenarbeit mit Orano Support SAS bekannt gegeben, um einen neuartigen Radio-Immuno-Konjugat (RIC) zur Krebsbehandlung zu entwickeln. Das Projekt zielt darauf ab, einen RIC der nächsten Generation zu schaffen, der Elemente von Auger-Elektronen (AE) in Kombination mit Defences Accum®-Technologie verwendet.
Die Accum®-Technologie geht auf die wesentlichen Einschränkungen von RICs ein, wie z.B. die endosomale Sequestrierung und die geringe nukleare Ansammlung. Defence hat verschiedene Accum®-Varianten mit unterschiedlichen Eigenschaften entwickelt und deren Produktion sichergestellt. Das Unternehmen hat außerdem die Fähigkeit einiger Accum®-Varianten patentrechtlich geschützt, Antikörper oder Antikörper-Konjugate in den Zellkern zu transportieren.
Defence hat in vitro und in vivo vorklinische Studien organisiert, die vom Radiopharmazeutischen Team der Canadian Nuclear Laboratories durchgeführt werden. Diese Zusammenarbeit zielt darauf ab, einen neuen Markt für die Krebsbehandlung zu erschließen, der auf vielversprechenden radioaktiven Therapeutika basiert, die AE-emittierende Radionuklide verwenden.
- Collaboration with Orano Support SAS to develop next-generation Radio-Immuno-Conjugate (RIC) for cancer treatment
- Accum® technology addresses key limitations of current RICs
- Secured production and manufacturing of Accum® variant peptides
- Patented ability of Accum® variants to deliver antibodies into the nucleus
- Arranged for preclinical studies with Canadian Nuclear Laboratories
- None.
Vancouver, British Columbia--(Newsfile Corp. - August 13, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is please to give an update on its Orano Support SAS partnership in the radiopharmaceuticals field, on behalf of Orano SAS ("Orano"), a world-renowned multinational nuclear company, headquartered in France.
Defence is developing in collaboration with Orano Support SAS, a novel Radio-Immuno-Conjugate ("RIC"), which includes an antibody to deliver the radioactivity specifically to cancer cells, a chelating agent linked to the radionuclide and specific Defence's Accum® variants, resulting in increasing the efficacy to treat cancers. The objective of this project is to develop the next generation of RIC exploiting the therapeutic dependency of Auger electron ("AE") emitter elements in closer proximity to nuclear DNA when combined with Defence's Accum® technology to induce its nuclear accumulation. AE emitters are very promising radionuclides for RIC development because of their very short pathlength radiation energy deposition, which decreases radiotoxicity on healthy tissues.
The Accum® moiety can overcome major limitations of RIC e.g. endosomal sequestration and poor nuclear accumulation, by destroying endosome membrane without affecting the plasma membrane nor mAbs specificity and by forcing the nuclear re-localization of the RIC. Defence has developed a multitude of Accum® variants with different biochemical properties and activities such as hydrophobicity and cytotoxicity.
Presently, no cancer treatment uses this type of radionuclides in RIC formulation due to the lack of efficacy induced by their endosomal entrapment and their dependency to be close to nuclear DNA. Defence's objective is to efficiently treat cancers with the potential of opening a new cancer therapy market based on a very promising radiotherapeutics implicating AE emitter radionuclides.
Defence has completed the conceptualization of the Accum® variant peptides and secure their production/manufacturing. Defence has showed and patented that some Accum® variants can be conjugated to an antibody or an antibody-conjugate to deliver it inside the nucleus. Defence is also pleased to have secured the in vitro and in vivo preclinical studies to be performed by the radiopharmaceuticals scientific team at the Canadian Nuclear Laboratories.
About Defence:
Defence Therapeutics is a publicly-traded clinical-stage biotechnology company working on engineering the next generation vaccines and ADC products using its proprietary platform. The core of Defence Therapeutics platform is the ACCUM® technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. As a result, increased efficacy and potency can be reached against catastrophic illness such as cancer and infectious diseases.
For further information:
Sebastien Plouffe, President, CEO and Director
P: (514) 947-2272
Splouffe@defencetherapeutics.com
www.defencetherapeutics.com
About Orano
As a recognized international operator in the field of nuclear materials, Orano delivers solutions to address present and future global energy and health challenges. Its expertise and mastery of cutting-edge technologies enable Orano to offer its customers high value-added products and services throughout the entire fuel cycle. Every day, the Orano group's 17,000 employees draw on their skills, unwavering dedication to safety and constant quest for innovation, with the commitment to develop know-how in the transformation and control of nuclear materials, for the climate and for a healthy and resource-efficient world, now and tomorrow.
Orano, giving nuclear energy its full value. Orano looks continuously at opportunities to value material derived from its core nuclear energy activities in a sustainable approach. Nuclear medicine therapy is one of the currently explored strand realized with the production of lead-212 (a rare radioisotope used for targeted alpha therapy) and clinical studies underway. Orano aims to further strengthen its development in the medical field and complete its pipeline with new promising radioisotopes.
Further information can be found at: https://www.orano.group.
Cautionary Statement Regarding "Forward-Looking" Information
This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.
Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/219710
FAQ
What is the purpose of Defence Therapeutics' collaboration with Orano Support SAS?
How does Defence Therapeutics' Accum® technology improve RIC efficacy?
What progress has Defence Therapeutics (DTCFF) made in developing its Accum® technology?
Where will Defence Therapeutics conduct preclinical studies for its RIC technology?
